AddLife AB Class B ( (ADDLF) ) has released its Q4 earnings. Here is a breakdown of the information AddLife AB Class B presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
AddLife AB is a European-based independent provider in the Life Science sector, offering a range of products, services, and technical support primarily to healthcare, research, and academia. The company operates through its two main business areas: Labtech and Medtech.
AddLife AB concluded the year 2024 with robust financial growth, particularly in the fourth quarter. The company reported an impressive 9% organic growth, a 24% increase in EBITA, and a 49% rise in cash flow, showcasing the success of its strategic efficiency efforts and strong demand in the market.
Throughout 2024, AddLife achieved a 6% increase in net sales, bringing the total to SEK 10,286 million. The EBITA margin was slightly lower at 11.3% compared to the previous year. However, the year was marked by significant improvements in both the Labtech and Medtech sectors, with Medtech experiencing a remarkable 46% increase in EBITA during the fourth quarter.
Looking ahead, AddLife anticipates continued growth opportunities in 2025, driven by ongoing healthcare demands and strategic initiatives to enhance cash flow and operational efficiency. The company remains well-positioned to navigate market uncertainties and aims to increase the pace of acquisitions, supported by its solid financial performance.
